News | August 02, 2022
Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
In clinical trials, treatment proved more effective than other therapies evaluated
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Subscribe To Our Newsletter & Stay Updated
